您当前的位置:
6-OAU
GPR84的合成激动剂,6-OAU(GTPL5846; 6-n-octylaminouracil)是GPR84激动剂,在PI assay中EC50值为105nM。
目录号: PC11492 纯度: ≥98%
CAS No. :83797-69-7
商品编号 规格 价格 会员价 是否有货 数量
PC11492-1mg 1mg ¥1179.92 请登录
PC11492-5mg 5mg ¥5309.64 请登录
PC11492-10mg 10mg ¥8849.40 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
6-OAU
中文别名
6-(辛基氨基)-2,4(1H,3H)-嘧啶二酮
英文名称
6-OAU
英文别名
6-(octylaMino)pyriMidine-2,4(1H,3H)-dione;GTPL5846;6-OAU;6-n-octylaminouracil;6-(octylamino)-1H-pyrimidine-2,4-dione;2,4(1H,3H)-Pyrimidinedione, 6-(octylamino)-;6-(Octylamino)-2,4(1H,3H)-pyrimidinedione;6-n-octyl aminouracil;AOB5243;BCP14892;BDBM50189502;Q27074016;6-(octylamino)-1,2,3,4-tetrahydropyrimidine-2,4-dione
Cas No.
83797-69-7
分子式
C12H21N3O2
分子量
239.31
包装储存
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
生物活性

6-OAU (GTPL5846) (6-n-octylaminouracil) is an GPR84 (G protein-coupled receptor 84) agonist, with an EC50 value of 105 nM. 6-OAU works as a chemoattractant to both PMNs and macrophages, and amplifies the proinflammatory cytokine IL-8, shows proinflammatory function. 6-OAU also displays anti-bacterial function.

性状

Solid

IC50 & Target[1][2]

ERK

 

体外研究(In Vitro)

GPR84 gene exhibits high expression in human polymorphonuclear leukocytes (PMNs) and macrophages, 6-OAU acts on proinflammatory function by activitating GPR84.
6-OAU (0.01 nM-0.1 mM; 1 h) activates human GPR84 in the presence of Gqi5 chimera with an EC50 value of 105 nM in HEK293 cells.
6-OAU (0, 6.25, 200 μM; 30 min) stimulates [S]GTP binding, accumulates phosphoinositides, and induces GPR84-EGFP internalization in a GPR84-dependent manner.
6-OAU (1 nM-1 mM; 1 h) provokes chemotaxis of PMNs in a concentration-dependent manner with an EC50 value of 318 nM.
6-OAU (0-10 μM; 4 h) increases the secretion of IL-8 from LPS-stimulated PMNs.
6-OAU (0-0.4 μM; 16 h) also amplifies TNF-α production from U937 macrophages.
6-OAU (2 μM; 4 h) decreases ERK phosphorylation and MCP-1 protein expression, (2 μM; 48 h) decreases MCP-1 secretion in macrophages .
6-OAU (2 μM; 24 h) reduces ROS production during B. abortus infection in RAW264.7 cells.
6-OAU (2 μM; 0, 30, and 60 min) inhibits adhesion and Brucella uptake in RAW264.7 cells and (2 μM; 30 min) shows anti-infection against Brucella and Salmonella infection.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay

Cell Line: B. abortus
Concentration: 0, 0.02, 0.2, 2 μM
Incubation Time: 0, 2, 24, 48, 72 hours
Result: Decreased B. abortus survivability begin at 48 h with a dose of 2 μM.

Western Blot Analysis

Cell Line: RAW264.7 cells infected with B. abortus
Concentration: 2 μM
Incubation Time: 4 hours
Result: Reduced ERK phosphorylation and MALT1 expression in RAW264.7 macrophages.
体内研究(In Vivo)

6-OAU activates GPR84 and results in making an inflammatory condition through chemokine production and chemotaxis in vivo.
6-OAU (10 mg/kg; i.v.) raises the blood CXCL1 level in rats.
6-OAU (1 mg/mL; s.c.) attracts both PMNs and macrophages into the air pouch.
6-OAU (2 μM, 100 mL/mouse; s.c.) augments resistance to Brucella infection, and reduces bacterial proliferation in spleens and livers.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Female Lewis rats(4-week-old)
Dosage: 10 mg/kg
Administration: Intravenous injection; collecting blood 3 h after injection
Result: Increased the elevation of a chemokine, CXCL1 concentration in the serum peaking at 3 h after the injection.
Animal Model: Rat air pouch model (4-week-old female rats)
Dosage: 1 mg/mL (PBS)
Administration: Subcutaneous injection; washing the cavity 4 h after injection
Result: Attracted both PMNs and macrophages into the air pouch, peaking at 4 h after the injection.
Animal Model: ICR female mice (7-week-old)
Dosage: 2 μM (100 μL/mouse)
Administration: Oral average; 7 days and another 14 days after treated mouse with B. abortus (2 × 105 CFU /100 μL; i.p.)
Result: Reduced bacterial proliferation in the liver and spleen, and decreased IFN-γ but augmented IL-6 serum level.
Lowed splenic weight of mice and splenic proliferation.
运输条件

Room temperature or refrigerated transportation.

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
参考文献
溶解度数据
体外研究: 

DMSO : 25 mg/mL (104.47 mM; Need ultrasonic)

配制储备溶液
浓度 溶剂体积 质量 1 mg 5 mg 10 mg
1 mM 4.1787 mL 20.8934 mL 41.7868 mL
5 mM 0.8357 mL 4.1787 mL 8.3574 mL
10 mM 0.4179 mL 2.0893 mL 4.1787 mL
*

产品不同,其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液;配成溶液后,建议分装保存,避免反复冻融造成的产品失效
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C 储存时,建议在 6 个月内使用,-20°C 储存时,建议在 1 个月内使用。

搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2